Elekta (EKTA B)
Free
No email, no account, no signup.
Pulling latest news for Elekta…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
HOLD
Sentiment
6/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Elekta is a Swedish medtech company selling radiotherapy systems (linear accelerators), radiosurgery (Gamma Knife), and oncology software. The company recently received FDA 510(k) clearance for Elekta Evo in the US and is executing a cost-saving program to improve margins.
Exchange
Nasdaq Stockholm
Sector
Radiotherapy medtech and oncology software
Market Cap
$2.2B
Market sentiment
Sentiment is **neutral-to-positive** and improving after the FDA news and cost focus, but discussion remains centered on FX/tariffs and US competitive dynamics.
Why HOLD ?
- **Hold**: upside catalysts (US Evo, cost savings) exist, but a meaningful portion may already be priced in.
- Await **Q4 results** and subsequent messaging to confirm margin and growth improvement.
- Key risks are **execution** (rollout/share) and external headwinds (FX/tariffs).
- Hold current position; consider a cautious add after Q4/CMD if margin targets are confirmed.
Recent News
- Since 2026-04-06, Elekta has invited investors to a Capital Markets Day (17 June 2026), participated in GITEX Future Health Africa (strategic focus on Africa), and is reported to have acquired Resonant Medical (about CAD 30m). At the same time, short interest has increased to ~12% of shares, and investor focus remains on potential US order intake after the FDA 510(k) clearance for Elekta Evo and delivery on the cost-savings program ahead of the Q4 report (28 May 2026).
Bull case
- **FDA clearance** for Elekta Evo can support near-term momentum.
- Early impact from **cost savings** may start to show.
Unlock to read more →
Bear case
- Ongoing **FX and tariff headwinds** may pressure reported results.
Unlock to read more →
Catalysts
17 Jun 2026 — Capital Markets Day (CMD)
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Elekta – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.